This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is It Time to Add Horace Mann (HMN) Stock to Your Kitty Now?
by Zacks Equity Research
A focus on improving product offerings, strengthening distribution and modernizing infrastructure bodes well for Horace Mann (HMN).
Horace Mann (HMN) Q3 Earnings Beat Estimates
by Zacks Equity Research
Horace Mann (HMN) delivered earnings and revenue surprises of 17.86% and 2.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MetLife (MET) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
MetLife (MET) delivered earnings and revenue surprises of 2.54% and 19.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Lemonade (LMND) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Lemonade (LMND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horace Mann (HMN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Horace Mann (HMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Everest Re (RE) in Q3 Earnings?
by Zacks Equity Research
Everest Re's (RE) Q3 results are likely to benefit from increases across all lines of business, strong renewal retention and growth in international operations, offset by higher cat loss.
Marsh & McLennan (MMC) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Marsh & McLennan's (MMC) third-quarter results reflect solid segmental contributions. Though robust international operations aid the Risk and Insurance Services segment, high costs dampen earnings.
Chubb's (CB) Q3 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Chubb's (CB) Q3 earnings are likely to reflect higher premiums and improved net investment income, offset by higher expenses.
W.R. Berkley (WRB) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Higher premium growth, increased net investment income and an improved expense ratio are likely to have aided W.R. Berkley's (WRB) third-quarter performance. The results are likely to be partly offset by higher expenses.
Why Should You Hold Assurant (AIZ) Stock in Your Portfolio?
by Zacks Equity Research
Higher trade-in volumes, international earnings, and income from fixed maturity securities, and a solid capital management policy continue to drive Assurant (AIZ).
Is a Beat in Store for Marsh & McLennan (MMC) in Q3 Earnings?
by Zacks Equity Research
Marsh & McLennan's (MMC) third-quarter results are likely to reflect revenue and earnings growth owing to solid performances by its Risk and Insurance Services, and Consulting segments.
What's in the Cards for Travelers (TRV) in Q3 Earnings?
by Zacks Equity Research
Travelers' (TRV) third-quarter results are likely to reflect new business premiums, strong retention rates, better pricing, partly offset by higher expenses.
Reasons Why EverQuote (EVER) Stock is an Attractive Pick
by Zacks Equity Research
EverQuote (EVER) is poised to benefit from inorganic growth, solid performance of automotive insurance providers and financial flexibility.
Here's Why You Should Add Radian Group (RDN) to Your Portfolio
by Zacks Equity Research
Improving mortgage insurance portfolio, declining claims, the well-performing homegenius segment and solid capital position poise Radian Group (RDN) well for growth.
MetLife (MET) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
MetLife (MET) delivered earnings and revenue surprises of 29.03% and 10.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CNO Financial (CNO) Tops Q2 Earnings Estimates
by Zacks Equity Research
CNO (CNO) delivered earnings and revenue surprises of 80.85% and 4.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Lemonade (LMND) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Lemonade (LMND) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Horace Mann (HMN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Horace Mann (HMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 15th
by Zacks Equity Research
ACER, HMN, and STT have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2022.
Horace Mann (HMN) Estimates Q2 Cat Loss, Trims 2022 Guidance
by Zacks Equity Research
Horace Mann's (HMN) lowered guidance for 2022 reflects estimated cat loss and equity market declines.
Horace Mann (HMN) Okays Share Buyback Authorization of $50M
by Zacks Equity Research
Horace Mann (HMN) estimates generating about $50 million in excess capital annually in 2022 and beyond to support growth initiatives, buy back shares and hike dividends
Everest Re (RE) Rewards Shareholders With 6.4% Dividend Hike
by Zacks Equity Research
Everest Re's (RE) recent 6.4% hike in dividend reflects its intention to enhance shareholders' value, supported by its strong financial position.
RLI Bolsters Shareholder Value, Increases Dividend by 4%
by Zacks Equity Research
RLI's recent 4% hike in dividend reflects its intention to enhance shareholders' value supported by its strong financial position.
Horace Mann (HMN) Q1 Earnings Lag Estimates
by Zacks Equity Research
Horace Mann (HMN) delivered earnings and revenue surprises of -31.91% and 2.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Eyes Q1 Earnings Beat on Cigna Healthcare Show
by Zacks Equity Research
Cigna's (CI) first-quarter 2022 results are likely to reflect improved pharmacy revenues in the Evernorth business.